Abstract
Palmoplantar pustulosis (PPP) is a chronic inflammatory disease characterized by sterile pustules on the palms and soles, and has an impact on patient quality of life. Spesolimab is a first-in-class humanized anti-interleukin 36 receptor monoclonal IgG antibody, previously investigated in a phase IIa PPP trial. In this phase IIb trial (NCT04015518), patients with moderate-to-severe PPP were assigned to 1 of 5 groups; they received a total subcutaneous loading dose of 1500/3000 mg spesolimab or placebo for the first 4 weeks followed by 300/600 mg spesolimab or placebo q4w.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
